← k3vl4r
Log inGet started →

IMNM (Immunome Inc) Price Forecast

AI-generated price forecast for Immunome Inc (IMNM) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.

As of August 2026: K3vl4r's AI model currently reads IMNM as 2/2 bearish · strong across its horizons (0 of 2 timeframes pointing up), with a last price of 25.06. See our public, auditable track record →

✓ Public, verifiable track record Live system status💎 Get the full AI report · pay with XRP

Last price

25.06

AI outlook

2/2 bearish · STRONG

Timeframes up

0 / 2

Share𝕏 Post✈ Telegram

IMNM forecast by horizon

HorizonDirectionProjected move (end of horizon)Bullish prob.
1-hour———
4-hour~8 weeks out———
Daily~5 months out▼ Down-38.91%0%
Weekly~1.9 years out▼ Down-38.08%—

Latest IMNM news

From the market-news feed the forecasts are read against.

  • Wedbush Reiterates Outperform on Immunome, Maintains $31 Price Target · Benzinga · Jul 21
  • Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors · Yahoo · Jul 20
  • What This Immunome Sale Means a Day Before a Big FDA Milestone · Motley Fool · Jul 12
  • Immunome Clears Key Regulatory Milestone as Lead Drug Goes Under FDA Review · Benzinga · Jul 8
  • Immunome's New Drug Application For Desmoid Tumors Treatment Accepted By FDA, April 28, 2027 Assigned As Prescription Drug User Fee Act Target Action Date · Benzinga · Jul 8

🔒

See the full IMNM forecast

Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.

Create a free account →

Already have one? Log in

IMNM forecast — frequently asked

Will IMNM go up?

K3vl4r's AI model currently reads IMNM as 2/2 bearish · STRONG — 0 of 2 forecast horizons point up, so the overall read is leaning to the downside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What is the IMNM price prediction for 2026?

K3vl4r's model projects IMNM toward $24.83 over the next ~5 months, a -0.4% move from $24.92. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

What price could IMNM reach?

Over its longest horizon (~~1.9 years), the model's projected target for IMNM is $24.96 (-0.4% vs $25.06). Confidence decreases the further out the horizon, so treat longer-range targets as one scenario, not a guarantee. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.

Part of Healthcare forecasts — browse the full sector.

More AI forecasts

AEMDAVTXAGENVNRXZURAPDSBALTALGNAUPHMBRXMGRXABEONXLSNDA

Will IMNM reach…?

Will IMNM reach $50.00?Will IMNM reach $100.00?Will IMNM reach $200.00?

Or see the full IMNM price prediction (2027–2040), or the forecast for today, tomorrow and this week.

Compare IMNM

IMNM vs AEMDIMNM vs AVTXIMNM vs AGENIMNM vs VNRXIMNM vs ZURAIMNM vs PDSB

Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.

K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.

Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.

k3vl4rTop PicksTrack recordChart indicatorsToday's outlookBiggest moversMarket heatmapForecasts by sectorAI reportsMarket videosCompareMethodologyBest AI toolsAboutFAQ◈ KVLHow KVL worksTokenomicsPricingX (Twitter)YouTube — daily showsTikTokTwitch — live forecastingDiscord community

Join the community on Discord and catch live forecasting on Twitch. Create a free account →

Forecasts are AI-generated; written analysis is AI-assisted and human-reviewed. Informational only, not financial advice. See Terms, Risk Disclosure, Privacy · Methodology · Status.